Selective segmental sclerotherapy of the liver cancer : Experimental and clinical study

选择性节段性肝硬化（SSS）是近年来发展起来的一种治疗肝脏恶性肿瘤的方法。在大鼠体内研究SSS的疗效和安全性。注射乙醇的肝段在注射后立即观察到黄白色区域，轮廓清晰，并在注射后2 - 3周内显示完全坏死。这一发现表明SSS可以诱导靶肝段的坏死。用中国墨水研究的结果表明，SSS相关的组织坏死可归因于乙醇的直接作用。仅观察到外周血中乙醇浓度轻微升高，在任何其他器官中均未发现组织学变化，仅检测到对肝和肾功能参数的轻微影响。结论：SSS治疗肝脏恶性肿瘤具有一定的临床应用价值。8例原发性肝癌患者经SSS治疗后，CT和血管造影显示肿瘤缩小，临床病程延长。

Segmental ablation of the liver by transportal ethanol injection, Selective Segmental Screlotherapy (SSS), were developed as the treatment of the malignant hepatic tumor. Therapeutic efficacy and safety of SSS were investigated in rats. The hepatic segments injected with ethanol were observed as a yellowish-white area with distinct outline immediately after injection and showed complete necrosis within 2 to 3 weeks after injection. This findings indicate that necrosis of a targeted hepatic segment can be induced by SSS.The result of investigation with China ink suggest that SSS-associated tissue necrosis is attributable to the direct action of ethanol. Only slight increase in the concentration of ethanol in peripheral blood was observed, and no histological change was found in any other organs, and only slight effect on hepatic and renal function parameters was detected. It is concluded that SSS should be clinically applicable for the treatment of malignant hepatic tumor. Eight patients with hepatocellular carcinoma were performed treatment by SSS.The tumor decreased in size and clinical course was demonstrated by CT and angiographic findings.